Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Up 1.4% – What’s Next?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) traded up 1.4% on Thursday . The company traded as high as $6.72 and last traded at $6.68. 6,934,035 shares changed hands during mid-day trading, a decline of 73% from the average session volume of 25,620,480 shares. The stock had previously closed at $6.58.

Wall Street Analysts Forecast Growth

RXRX has been the subject of several recent research reports. KeyCorp dropped their price target on shares of Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating for the company in a research report on Wednesday, January 8th. Cowen reissued a “hold” rating on shares of Recursion Pharmaceuticals in a report on Friday, February 28th. Leerink Partners decreased their price target on Recursion Pharmaceuticals from $7.00 to $6.00 and set a “market perform” rating on the stock in a research note on Friday, February 28th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $11.00 price objective on shares of Recursion Pharmaceuticals in a research note on Thursday, February 6th. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $8.25.

Recursion Pharmaceuticals Stock Down 5.2 %

The company has a market cap of $2.44 billion, a P/E ratio of -4.08 and a beta of 0.86. The business’s 50 day moving average price is $7.68 and its 200-day moving average price is $7.08. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.35 and a quick ratio of 4.35.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its quarterly earnings data on Friday, February 28th. The company reported ($0.53) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.17). Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The business had revenue of $4.60 million during the quarter, compared to analyst estimates of $19.04 million. During the same period in the prior year, the firm posted ($0.42) EPS. Recursion Pharmaceuticals’s revenue for the quarter was down 57.8% compared to the same quarter last year. On average, analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the stock. Ensign Peak Advisors Inc lifted its position in shares of Recursion Pharmaceuticals by 0.3% during the fourth quarter. Ensign Peak Advisors Inc now owns 410,286 shares of the company’s stock worth $2,774,000 after purchasing an additional 1,300 shares in the last quarter. Farther Finance Advisors LLC raised its position in Recursion Pharmaceuticals by 21.1% in the 4th quarter. Farther Finance Advisors LLC now owns 7,757 shares of the company’s stock worth $52,000 after purchasing an additional 1,353 shares during the last quarter. Axxcess Wealth Management LLC lifted its holdings in Recursion Pharmaceuticals by 4.3% during the 3rd quarter. Axxcess Wealth Management LLC now owns 43,884 shares of the company’s stock worth $289,000 after buying an additional 1,795 shares in the last quarter. Summit Investment Advisors Inc. boosted its position in Recursion Pharmaceuticals by 7.8% in the 4th quarter. Summit Investment Advisors Inc. now owns 26,030 shares of the company’s stock valued at $176,000 after buying an additional 1,875 shares during the last quarter. Finally, Wedmont Private Capital increased its stake in shares of Recursion Pharmaceuticals by 10.6% in the 4th quarter. Wedmont Private Capital now owns 20,943 shares of the company’s stock valued at $144,000 after buying an additional 2,000 shares during the period. Institutional investors own 89.06% of the company’s stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.